TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP Life Science Investing
CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign Life Science Investing
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials Life Science Investing
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting Life Science Investing
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline Biotech Investing
Cizzle Brands® Corporation Announces Multi-Year Agreement with MLSE to Make CWENCH Hydration the Official Sports Drink of the Toronto Maple Leafs® Biotech Investing
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies Life Science Investing
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock Biotech Investing
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences Life Science Investing
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis Biotech Investing
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer Life Science Investing
Quantum-Si Presents Interim Proteus Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
